Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioids And The Limits Of FDA Power

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA adds a MedGuide for immediate-release opioids and shrinks their indication; the products seemed destined for an educational REMS, but is there even more the agency could do?

You may also be interested in...

Califf Says Opioid Labeling Changes, Withdrawals Still Possible

The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.

Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review

Advisory committee to discuss data on abuse of Opana ER and generic oxymorphone extended-release and immediate-release products.

Califf Sets Exit At FDA, Ostroff Could Return To Acting Commissioner Post

Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts